Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.
Dengue vaccine
| Vaccine description | |
|---|---|
| Target | Dengue fever |
| Vaccine type | Attenuated |
| Clinical data | |
| Trade names | Dengvaxia, Qdenga |
| Other names | CYD-TDV |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
Dengue vaccine is a vaccine used to prevent dengue fever in humans.[9] Development of dengue vaccines began in the 1920s but was hindered by the need to create immunity against all four dengue serotypes.[10] As of 2023, there are two commercially available vaccines, sold under the brand names Dengvaxia and Qdenga.[11][12]
Dengvaxia is only recommended in those who have previously had dengue fever or populations in which most people have been previously infected due to phenomenon known as antibody-dependent enhancement.[13] The value of Dengvaxia is limited by the fact that it may increase the risk of severe dengue in those who have not previously been infected.[14][13] In 2017, more than 733,000 children and more than 50,000 adult volunteers were vaccinated with Dengvaxia regardless of serostatus, which led to a controversy.[15] Qdenga is designated for people not previously infected.[16]
There are other vaccine candidates in development including live attenuated, inactivated, DNA and subunit vaccines.[10]
- ^ "Dengvaxia dengue tetravalent vaccine (live, attenuated), powder and diluent for suspension for injection (275964)". Therapeutic Goods Administration (TGA). 26 May 2022. Retrieved 9 April 2023.
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
- ^ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
- ^ "Vacina contra a dengue: aplicação começa nesta semana em clínicas particulares" [Dengue vaccine: administration starts this week in private clinics]. CNN Brazil (in Portuguese). 26 June 2023. Retrieved 29 June 2023.
- ^ "Qdenga powder and solvent for solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 22 March 2023. Retrieved 9 April 2023.
- ^ Cite error: The named reference
Dengvaxia FDA labelwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Dengvaxia EPARwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Qdenga EPARwas invoked but never defined (see the help page). - ^ Cite error: The named reference
AHFS2019was invoked but never defined (see the help page). - ^ a b McArthur MA, Sztein MB, Edelman R (August 2013). "Dengue vaccines: recent developments, ongoing challenges and current candidates". Expert Review of Vaccines. 12 (8): 933–953. doi:10.1586/14760584.2013.815412. PMC 3773977. PMID 23984962.
- ^ World Health Organization (24 November 2023). "Meeting of the Strategic Advisory Group of Experts on Immunization, September 2023: conclusions and recommendations". Weekly Epidemiological Record. 98 (47): 599–620. hdl:10665/374327.
- ^ Freedman DO (November 2023). "A new dengue vaccine (TAK-003) now WHO recommended in endemic areas; what about travellers?". J Travel Med. 30 (7): 1–3. doi:10.1093/jtm/taad132. PMID 37847608.
- ^ a b World Health Organization (September 2018). "Dengue vaccine: WHO position paper – September 2018". Weekly Epidemiological Record. 93 (36): 457–76. hdl:10665/274316.
- ^ Redoni M, Yacoub S, Rivino L, Giacobbe DR, Luzzati R, Di Bella S (July 2020). "Dengue: Status of current and under-development vaccines". Reviews in Medical Virology. 30 (4): e2101. doi:10.1002/rmv.2101. hdl:1983/6d38d9b6-8e1b-4a84-85e3-edab4fc41957. PMID 32101634. S2CID 211536962.
- ^ Lopez V (4 December 2017). "DOJ orders NBI to investigate P3.5-B dengue vaccine scandal". STAT. Retrieved 14 December 2017.
- ^ "Takeda Begins Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic Countries" (Press release). Takeda Pharmaceutical Company Limited. 25 March 2021. Retrieved 28 March 2021.
Previous Page Next Page
